🇺🇸 FDA
Patent

US 10781242

Interleukin-2 fusion proteins and uses thereof

granted A61KA61K38/00A61K38/1761

Quick answer

US patent 10781242 (Interleukin-2 fusion proteins and uses thereof) held by Medicenna Therapeutics Inc. expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medicenna Therapeutics Inc.
Grant date
Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K38/00, A61K38/1761, A61K38/2013, A61P